Key Points
- Insider sale: Billiontoone insider Nancy Joann Johnson sold 801 shares on July 1 at an average price of $124.91, totaling about $100,053. The sale was made under a pre-arranged Rule 10b5-1 trading plan.
- Recent insider activity: Johnson also sold 10,582 shares on June 9 and 3,418 shares on June 8, indicating a larger recent pattern of selling in the stock.
- Company and analyst backdrop: Billiontoone recently reported strong quarterly results, with EPS of $0.34 and revenue up 83.8% year over year, while analysts currently rate the stock a Moderate Buy with a consensus target price of $126.00.
Billiontoone, Inc. (NASDAQ:BLLN - Get Free Report) insider Nancy Joann Johnson sold 801 shares of the firm's stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $124.91, for a total value of $100,052.91. Following the completion of the sale, the insider directly owned 21,099 shares in the company, valued at approximately $2,635,476.09. The trade was a 3.66% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Nancy Joann Johnson also recently made the following trade(s):
- On Tuesday, June 9th, Nancy Joann Johnson sold 10,582 shares of Billiontoone stock. The stock was sold at an average price of $100.47, for a total transaction of $1,063,173.54.
- On Monday, June 8th, Nancy Joann Johnson sold 3,418 shares of Billiontoone stock. The shares were sold at an average price of $99.28, for a total transaction of $339,339.04.
Billiontoone Trading Down 0.7%
Shares of Billiontoone stock opened at $122.59 on Tuesday. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.92 and a quick ratio of 10.58. Billiontoone, Inc. has a 1 year low of $61.96 and a 1 year high of $138.70. The firm has a market cap of $5.64 billion and a PE ratio of 225.55. The company has a 50 day simple moving average of $97.00 and a two-hundred day simple moving average of $88.08.
Billiontoone (NASDAQ:BLLN - Get Free Report) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $0.34 EPS for the quarter, topping analysts' consensus estimates of $0.01 by $0.33. The company had revenue of $108.39 million during the quarter, compared to the consensus estimate of $95.81 million. During the same period in the previous year, the company earned ($0.39) EPS. Billiontoone's quarterly revenue was up 83.8% on a year-over-year basis. Analysts expect that Billiontoone, Inc. will post 0.93 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Billiontoone
Hedge funds and other institutional investors have recently made changes to their positions in the business. Baillie Gifford & Co. purchased a new position in Billiontoone during the 4th quarter valued at $103,786,000. Massachusetts Financial Services Co. MA purchased a new stake in shares of Billiontoone in the 4th quarter worth about $13,373,000. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of Billiontoone during the 4th quarter valued at about $1,348,000. UBS Group AG bought a new stake in shares of Billiontoone during the 4th quarter valued at about $2,586,000. Finally, Seven Grand Managers LLC purchased a new position in shares of Billiontoone during the fourth quarter valued at about $2,046,000.
Analyst Ratings Changes
Several brokerages have issued reports on BLLN. Guggenheim started coverage on Billiontoone in a research note on Monday, June 29th. They issued a "buy" rating and a $125.00 target price for the company. BTIG Research reduced their target price on shares of Billiontoone from $140.00 to $130.00 and set a "buy" rating on the stock in a report on Thursday, May 7th. Weiss Ratings raised shares of Billiontoone from a "sell (d)" rating to a "sell (d+)" rating in a research note on Tuesday, June 23rd. Finally, JPMorgan Chase & Co. lifted their price objective on Billiontoone from $120.00 to $125.00 and gave the stock an "overweight" rating in a report on Thursday, May 7th. Six investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $126.00.
View Our Latest Analysis on BLLN
Billiontoone Company Profile
(
Get Free Report)
BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.
BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
